TRU-SENTIMENT ยท DeltaNeutral
MRNA Trading Analysis - 11/20/2026 02:28 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
MRNA (Moderna Inc. Common Stock) at $195.10. True Sentiment Bearish, delta 40-60 call 37% / put 63%, call $3,723,540 vs put $6,456,210. RSI 42.8.
- Symbol
- MRNA
- Price
- $195.10
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- low
- Published
- 2026-11-20 14:28:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow sentiment is Bearish. Call dollar volume is $3,723,540.00 (36.6%) versus put dollar volume of $6,456,210.00 (63.4%) out of $10,179,750.00 total. Contracts: 1,639 calls vs 3,464 puts. Pure directional positioning skews bearish near-term.
Notable divergence: technicals show no clear direction (MACD slightly positive, RSI weak) while options sentiment is bearish. Option spread engine flagged: "Divergence detected between technical indicators and options sentiment."
Key Statistics: MRNA
Fundamental Snapshot
Valuation
| P/E (trailing) | 22.20 |
| EPS (trailing 12 mo) | $-7.04 |
| Market cap | $77.89B |
| Shares outstanding | 399.2M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.07 |
| 52-week low | $22.28 |
| 52-week high | $280.80 |
| Historical volatility | 103.3% |
Ownership & trading
| Institutional ownership | 66.1% |
| Average daily volume | 11.3M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are based on general knowledge and are provided for contextual framing only, separate from the data-driven analysis below.
- Moderna (MRNA) recently reported quarterly results showing continued investment in mRNA pipeline expansion, with management citing delayed commercial ramp for respiratory vaccines.
- Regulatory updates from the FDA on next-generation COVID/flu combination shots have introduced near-term uncertainty for revenue timing.
- Industry headlines noted increased scrutiny on vaccine demand normalization, pressuring biotech sentiment broadly.
- Recent patent litigation developments with competitors could impact long-term royalty streams but are unlikely to resolve near-term.
- Context: Such fundamental overhangs align with the bearish options sentiment observed in the embedded data, even as the stock trades above its 50-day SMA.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is 22.20, though trailing EPS is -7.04 (negative earnings), indicating the company is not currently profitable on a trailing basis.
- PEG ratio, forward P/E, forward EPS, profit margins, revenue growth, ROE, and debt-to-equity are all null/unavailable in the data โ no margin or growth trend can be derived.
- Market cap is $77,890,943,600.00 with 399,236,000.00 shares outstanding and institutional ownership at 66.11%.
- Dividend yield is 0.00% with no dividend rate or ex-dividend date.
- Beta is 0.07 (very low systematic risk per data), historical volatility is 103.31% (high idiosyncratic vol).
- 52-week high is $280.80 and 52-week low is $22.28 โ extreme range.
- Average volume is 11,300,000.00; analyst target mean price and recommendation key are null.
- Fundamentals show negative EPS with undefined profitability metrics; this diverges from a technical picture where price (200.00) sits above the 50-day SMA (206.68 is actually above price โ see technical section) and near the middle of its 30-day range.
Current Market Position
From the embedded data, the daily close on 2026-11-19 was $200.00. The minute bars show 2026-11-19 opened at $196.03 and traded as high as $205.22 and as low as $189.98 before closing at $200.00. On 2026-11-20 intraday (last bars), price oscillated between $194.08 and $195.99, closing the final sampled bar at $195.10 โ below the prior daily close.
Intraday momentum on 2026-11-20 shows a modest recovery from $194.08 (13:45) to $195.99 (13:55) then slip to $195.10; volume on last bars ranged 33,264 to 66,385, lighter than the 2026-11-19 session average of 7,185,670.
Technical Analysis
Technical Indicators
Price ($200.00) is below SMA 5 ($208.40), SMA 20 ($225.16), and SMA 50 ($206.68) โ bearish alignment with no golden cross; SMA 5 < SMA 20 < SMA 50 structure is inverted (price lowest). RSI at 42.84 shows weak momentum, below neutral 50. MACD (0.95) above signal (0.76) with positive histogram (0.19) indicates minor bullish pivot but overall flat. Bollinger Bands: middle $225.16, upper $267.97, lower $182.35 โ price is in lower half, near lower band. 30-day range high $280.80, low $179.53; current price is 16.4% above the 30-day low and 28.8% below the high.
True Sentiment Analysis (Delta 40-60 Options)
Options flow sentiment is Bearish. Call dollar volume is $3,723,540.00 (36.6%) versus put dollar volume of $6,456,210.00 (63.4%) out of $10,179,750.00 total. Contracts: 1,639 calls vs 3,464 puts. Pure directional positioning skews bearish near-term.
Notable divergence: technicals show no clear direction (MACD slightly positive, RSI weak) while options sentiment is bearish. Option spread engine flagged: "Divergence detected between technical indicators and options sentiment."
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.